ArticleMolecular and clinical oncology2026
Sequential immune checkpoint inhibition after palliative radiotherapy in patients with advanced head and neck squamous cell carcinoma: A retrospective cohort study.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) frequently presents at an advanced stage, where curative options are often not feasible. Palliative radiotherapy (RT) can relieve symptoms and improve performance status, potentially enabling systemic therapy. Immune checkpoint inhibitors (ICIs) have a survival benefit in recurrent and metastatic HNSCC; however, the optimal sequencing of RT and ICIs remains to be elucidated. The present study aimed to evaluate the clinical outcomes of ICI therapy administered after palliative RT in patients with advanced HNSCC. Consecutive patients with advanced HNSCC treated at The University of Tokyo Hospital (Tokyo, Japan) between January 2017 and December 2024 were retrospectively reviewed. Eligible patients received initial palliative RT, with or without subsequent ICIs within 6 months (RT-ICI vs. RT groups). Clinical data, including demographics, RT parameters, treatment regimens and outcomes, were collected. Overall survival (OS) and progression-free survival (PFS) analyses were performed using the Kaplan-Meier method and Cox proportional hazards models. Among 74 patients (median age, 75 years; 82% male), 17 received ICIs following RT. The RT-ICI group achieved a 2-year OS rate of 55.8% compared with 5.7% in the RT group (P<0.001). Median PFS time in the RT-ICI group was 12.7 months, with a 2-year PFS rate of 20.9%. Multivariate analysis confirmed RT-ICI treatment [hazard ratio (HR) 0.22, 95% confidence interval (CI) 0.09-0.55; P=0.001], higher biologically effective dose (≥39 Gy; HR 0.46, 95% CI 0.24-0.91; P=0.025) and preserved performance status (HR 1.99, 95% CI 1.02-3.88; P=0.043) as independent predictors of OS. Grade 3 or higher immune-related adverse events occurred in three patients (17.6%). In conclusion, sequential ICI therapy after palliative RT was revealed to be associated with improved survival outcomes in patients with advanced HNSCC. Higher RT dose was also associated with a better survival; however, no causal or mechanistic conclusions can be drawn from this observation. Further prospective studies are warranted to confirm these findings, and to clarify the optimal sequencing and dosing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.